3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
42
Leukemia
35
Lymphoma
19
Myelodysplastic Syndromes
15
Precursor Cell Lymphoblastic Leukemia-Lymphoma
14
Lymphoma, Non-Hodgkin
13
Hodgkin Disease
13
Leukemia, Myeloid, Acute
12
Multiple Myeloma
11
Myeloproliferative Disorders
9
Recurrence
8
Lymphoma, T-Cell, Peripheral
8
Lymphoma, Mantle-Cell
7
Lymphoma, Large B-Cell, Diffuse
7
Lymphoma, B-Cell, Marginal Zone
7
Burkitt Lymphoma
7
Lymphoma, T-Cell, Cutaneous
6
Lymphoma, Large-Cell, Immunoblastic
6
Lymphoma, Follicular
6
Hematologic Neoplasms
6
Congenital Abnormalities
6
Waldenstrom Macroglobulinemia
5
Sezary Syndrome
5
Primary Myelofibrosis
5
Neoplasms, Plasma Cell
5
Mycosis Fungoides
5
Leukemia, Myeloid, Chronic-Phase
5
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
5
Anemia, Aplastic
5
Myelodysplastic-Myeloproliferative Diseases
4
Interventions
teriflunomide
1
Natalizumab
1
Interferon beta-1b
1
Fingolimod Hydrochloride
1
Dimethyl Fumarate
1
Alemtuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Multiple Sclerosis, Relapsing-Remitting
×
Alemtuzumab
×
Clear all
NCT06705608
2024-11-26
MS; FTY720
University of British Columbia
Completed
4,000 enrolled